Fig. 7
Gene expression of lipid synthesizing and metabolizing enzymes in neuronal tissue of SAFit2-treated paclitaxel mice. After twelve days, the expression of phospholipases (A, B), lipoxygenases (C–F), epoxygenase (G), sphingosine kinases (H, I) and ceramide synthases (J, K) was assessed via qPCR. The expression levels of vehicle and SAFit2-treated animals were normalized to the expression levels of naïve animals. The data represent the mean ± SEM from 3–4 mice per group, measured in technical triplicates, respectively. * p < 0.05, ** p < 0.01, *** p < 0.001 one-way ANOVA with Tukey´s post hoc test was conducted per tissue. DRGs dorsal root ganglia, SC spinal cord, SAFit2 selective antagonist of FKBP51 by induced fit 2, cPLA2 cytosolic phospholipase A2, iPLA2 calcium-independent phospholipase A2, ALOX arachidonate lipoxygenase, CYP2J6 cytochrome P450 family 2 subfamily j polypeptide 6c, COX2 cyclooxygenase 2, SphK1/2 sphingosine kinase 1/ 2, CerS ceramide synthase